<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232178</url>
  </required_header>
  <id_info>
    <org_study_id>INN-CB-013</org_study_id>
    <nct_id>NCT02232178</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant</brief_title>
  <official_title>A Randomized, Blinded, Inpatient Study to Investigate the Pharmacokinetics, Relative Bioavailability and Safety of 2 Doses of the XaraColl® Bupivacaine Collagen Implant (200 and 300 mg Bupivacaine Hydrochloride) Compared to Bupivacaine Hydrochloride Infiltration (150 mg) After Open Laparotomy Hernioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocoll</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innocoll</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the pharmacokinetic profile of 2 doses of the XaraColl® implant after open laparotomy
      hernioplasty and assess the relative bioavailability of Xaracoll compared to a local
      bupivacaine infiltration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inguinal hernioplasty is a common surgery. Common surgical methods used include laparoscopic
      and open placement of synthetic mesh. Managing postoperative pain and preventing morbidity
      after open mesh hernioplasty remain considerable medical challenges.

      Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile.
      Collagen is a protein that is found in all mammals. The Xaracoll implant is a thin flat
      sponge made out of collagen that comes from cow tendons and contains bupivacaine. When
      inserted into a surgical site, the collagen breaks down and bupivacaine is released at the
      surgical site to provide postoperative pain control.

      This study will assess the pharmacokinetic profile of 2 doses of the XaraColl implant after
      open laparotomy hernioplasty and assess the relative bioavailability of the Xaracoll implant
      compared to a local bupivacaine infiltration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>Through 96 hours after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Safety</measure>
    <time_frame>Through 24 hours after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Hernioplasty</condition>
  <arm_group>
    <arm_group_label>2 100mg Xaracoll implants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivacaine HCl implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 100mg Xaracoll implants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivacaine HCl implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150mg Bupivacaine HCl injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 100mg Xaracoll implants</intervention_name>
    <arm_group_label>2 100mg Xaracoll implants</arm_group_label>
    <other_name>Bupivacaine HCl implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 100mg Xaracoll implants</intervention_name>
    <arm_group_label>3 100mg Xaracoll implants</arm_group_label>
    <other_name>Bupivacaine HCl implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150mg Bupivacaine HCl injection</intervention_name>
    <arm_group_label>150mg Bupivacaine HCl injection</arm_group_label>
    <other_name>Bupivacaine HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man or woman who is ≥ 18 years of age

          2. Has a planned unilateral inguinal hernioplasty (open laparotomy, tension free
             technique)

          3. If female, is nonpregnant

        Exclusion Criteria:

          1. Scheduled for bilateral inguinal hernioplasty or other significant concomitant
             surgical procedures

          2. Has undergone major surgery within 3 months of the scheduled hernioplasty or plans to
             undergo another laparotomy procedure within 30 days postoperatively

          3. Has any clinically significant unstable cardiac, neurological, immunological, renal,
             hepatic or hematological disease or any other condition that, in the opinion of the
             investigator, could compromise the patient's welfare, ability to communicate with the
             study staff or otherwise contraindicate study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Prior, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Innocoll</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shoals Medical Trials Inc</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wexner Medical Center at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Concepts</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victory Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unilateral inguinal hernioplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 17, 2017</submitted>
    <returned>April 27, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

